Angiogenesis in non-small cell lung cancer: imaging with perfusion computed tomography

Area of Science:

• Oncology
• Radiology
• Medical Imaging

Background:

• Vascular manipulation is a promising therapeutic strategy for advanced non-small cell lung cancer (NSCLC).
• Bevacizumab is approved for first-line NSCLC therapy; other vascular-targeting agents are in clinical trials.
• Perfusion computed tomography (CT) is an emerging biomarker for NSCLC.

Purpose of the Study:

• To evaluate the role of perfusion CT as a biomarker in advanced NSCLC.
• To assess the utility of perfusion CT in monitoring antiangiogenic and vascular-targeting therapies.
• To determine the prognostic and predictive value of perfusion CT in NSCLC.

Main Methods:

• Utilized advanced volumetric perfusion CT techniques for whole tumor evaluation.
• Assessed tumor perfusion and angiogenesis as measures of vascularity.
• Correlated imaging findings with therapeutic response and patient outcomes (implied).

Main Results:

• Perfusion CT provides high-quality, whole tumor evaluation with current volumetric techniques.
• Perfusion CT can measure tumor perfusion and angiogenesis.
• Perfusion CT offers potential for pharmacodynamic information and monitoring treatment effects.

Conclusions:

• Perfusion CT is a valuable tool for assessing tumor vasculature in NSCLC.
• It can provide crucial pharmacodynamic data in early clinical trials.
• Perfusion CT holds potential for prognostic and predictive applications in NSCLC management.